osimertinib and Hepatitis-B--Chronic

osimertinib has been researched along with Hepatitis-B--Chronic* in 1 studies

Other Studies

1 other study(ies) available for osimertinib and Hepatitis-B--Chronic

Article	Year
Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report. Thoracic cancer, 2022, Volume: 13, Issue:7 Osimertinib is the most efficient first-line drug, with least adverse effects, for metastatic non-small-cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. Herein, we present a 68-year-old woman who had chronic hepatitis B with aggressive NSCLC and received osimertinib as cancer treatment for 4.5 months. This is the first report of mortality due to osimertinib-related acute fulminant hepatitis. Clinicians should routinely arrange for hepatitis B virus (HBV) screening and prescribe antiviral drugs to patients with chronic HBV infection before osimertinib administration. Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Hepatitis B, Chronic; Humans; Lung Neoplasms; Massive Hepatic Necrosis; Mutation; Protein Kinase Inhibitors	2022

Article

Year

Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report.

Thoracic cancer, 2022, Volume: 13, Issue:7

Osimertinib is the most efficient first-line drug, with least adverse effects, for metastatic non-small-cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. Herein, we present a 68-year-old woman who had chronic hepatitis B with aggressive NSCLC and received osimertinib as cancer treatment for 4.5 months. This is the first report of mortality due to osimertinib-related acute fulminant hepatitis. Clinicians should routinely arrange for hepatitis B virus (HBV) screening and prescribe antiviral drugs to patients with chronic HBV infection before osimertinib administration.

Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Hepatitis B, Chronic; Humans; Lung Neoplasms; Massive Hepatic Necrosis; Mutation; Protein Kinase Inhibitors

2022